Ethernet Global Data Protocol

IPG Modernizes Identity Resolution with Launch of Real ID Cloud Solution

Retrieved on: 
星期二, 十月 17, 2023

Real ID enables marketers to recognize the real people behind the scattered data points, swiftly creating accurate, holistic customer views that tap into Acxiom’s best-in-class data assets.

Key Points: 
  • Real ID enables marketers to recognize the real people behind the scattered data points, swiftly creating accurate, holistic customer views that tap into Acxiom’s best-in-class data assets.
  • Real ID accelerates growth for brands by enhancing a marketer’s existing first-party data, without the cost, complexity, and risk of moving personally identifiable information (PII).
  • "At a time when personalized brand experiences are what every brand and marketer need to deliver, Real ID in the cloud addresses an industry need for identity resolution tools that prioritize consumer privacy in a post-cookie world.
  • Acxiom and FCB, the global creative network within IPG, are using Real ID in the Cloud for shared clients to drive insights and accelerate growth for brands.

INTRODUCING THE SIMPLE TRUTH REPORT

Retrieved on: 
星期三, 八月 2, 2023

LONDON, Aug. 2, 2023 /PRNewswire/ -- Simple stands for honesty, uncomplicated beauty, and creating effective solutions gentle enough for even the most sensitive types. This is The Simple Truth.

Key Points: 
  • This is The Simple Truth.
  • The research and analysis behind The Simple Truth report was designed by Beauty SEEN Limited on our behalf, while fieldwork was conducted by Savanta Group Limited among 2,003 UK-based skincare consumers, men and women, aged 18+ in February 2023.
  • This is where the Simple Truth Report comes in to help provide clarity and straightforward facts.
  • The report includes detailed findings on misinformation in the skincare industry and myths, social media's role , consumer confusion, consumers' desire for change, and Simple's commitment to The Simple Truth.

Luxe travel back on the itinerary as travelers seek 'wow factor'

Retrieved on: 
星期三, 十一月 2, 2022

"All segments of travel are expected to surge due to pent-up demand and consumer savings**.

Key Points: 
  • "All segments of travel are expected to surge due to pent-up demand and consumer savings**.
  • Key reasons include disconnecting from the routine and stresses of home, connecting with new people, cultures and experiences, and enhancing wellbeing.
  • Travelers are also seeking memorable, sustainable experiences," says Stephane Thomas, MAD Design USA Director.
  • Now we're witnessing even greater demand as operators seek to enhance aesthetics to entice luxury travellers."

Novotech's APAC and USA Leadership Teams at BIO 2022

Retrieved on: 
星期二, 六月 14, 2022

#4907

Key Points: 
  • #4907
    Book a meeting with one of the Novotech experts at BIO here.
  • Novotech now has a workforce of ~2,500 clinical trial professionals across Australia, South Korea, Greater China, Southeast Asia, India, South Africa and the US.
  • The APAC region was the largest contributor, with more than 50% of the trials followed by the US (29%) and the EU5 (17%).
  • It has been instrumental in the success of approximately 3,700 clinical trials across a broad range of therapeutic areas.

Novotech Sponsors Endpoints ASCO 2022 Expert Panel on Accelerating Oncology Clinical Trials in China

Retrieved on: 
星期一, 六月 6, 2022

With experienced clinical teams in both regions, Novotech will share real-world success strategies for biotechs undertaking global clinical development programs."

Key Points: 
  • With experienced clinical teams in both regions, Novotech will share real-world success strategies for biotechs undertaking global clinical development programs."
  • According to Global Data whitepaper: EVOLUTION OF CLINICAL TRIALS IN THE ASIA PACIFIC REGION COMPARED TO THE US AND THE EU5*, over the past 5 years the growth of oncology trials (CAGR of 25%) in China outpaced other countries.
  • Novotech recently announced a partnership and investment in tech firm Prospection to support accelerated clinical trials with healthcare data analytics using real-world data.
  • Novotech is well positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally.

Novotech Sponsors Pre-ASCO China Summit Expert Panels on Early Phase Oncology Trials and Regulatory Strategy for China and US

Retrieved on: 
星期四, 六月 2, 2022

The Novotech sponsored Summit sessions are:

Key Points: 
  • The Novotech sponsored Summit sessions are:
    China offers a compelling solution for expedited clinical trials especially in oncology with its vast patient populations and world-class KOLs.
  • - In addition, over the last five years more 70,000 new clinical trials were registered in the APAC region, the US, and the EU5.
  • Novotech recently announced a partnership and investment in tech firm Prospection to support accelerated clinical trials with healthcare data analytics using real-world data.
  • Novotech is well positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally.

Antibe Therapeutics Provides Update on Otenaproxesul and Expanded Drug Pipeline

Retrieved on: 
星期四, 十月 14, 2021

Short-term pain management has its own considerable challenges, not the least being a continued reliance on opioids, for which otenaproxesul is an ideal fit.

Key Points: 
  • Short-term pain management has its own considerable challenges, not the least being a continued reliance on opioids, for which otenaproxesul is an ideal fit.
  • In collaboration with outside experts and key opinion leaders, the Company has completed a comprehensive assessment of the AME study data.
  • Antibes lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for acute pain and the treatment of osteoarthritis.
  • Antibe Therapeutics assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.